• Molecular NameTeniposide
  • SynonymTeniposido [INN-Spanish]; Teniposidum [INN-Latin]
  • Weight670.688
  • Drugbank_IDDB00444
  • ACS_NO29767-20-2
  • Show 3D model
  • LogP (experiment)1.24
  • LogP (predicted, AB/LogP v2.0)1.65
  • pkaN/A
  • LogD (pH=7, predicted)1.65
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-5.52
  • LogSw (predicted, AB/LogsW2.0)0.11
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors3
  • No.of HBond Acceptors13
  • No.of Rotatable Bonds6
  • TPSA189.07
  • StatusFDA approved
  • AdministrationIntravenous
  • PharmacologyA chemotherapeutic medication mainly used in the treatment of childhood acute lymphocytic leukemia (ALL). It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability41.0
  • Protein binding99.0
  • Volume of distribution (VD)0.17~0.27 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP2C19-mediated)
  • Half life5 h
  • ExcretionRenal and fecal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A